Compare Mongodb Inc (MDB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Merck & Co., Inc. — how do they compare? Mongodb Inc trades at $372 (market cap $29.24B), while Merck & Co., Inc. trades at $142.05 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 12× Mongodb Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Merck & Co., Inc. for 98 Days on average.
| MDB | MRK | |
|---|---|---|
Market Cap | $29.24B | $352.29B |
Volume | 1,304,995 | 6,348,796 |
Sector | Technology | Health |
52-Week High | $472.29 | $156.43 |
52-Week Low | $225.95 | $82.49 |
Typical Hold Time | 45 Days | 98 Days |
Enterprise Value | $26.86B | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
